Drug-induced Skin Lesions in Cynomolgus Macaques Treated with Metabotropic Glutamate Receptor 5 (mGluR5) Negative Allosteric Modulators

Toxicologic Pathology

Volumn 43, Issue 7, 2015, Pages 995-1003

  Palanisamy, Gopinath S ^a   Marcek, John M ^b   Cappon, Gregg D ^b   Whritenour, Jessica ^b   Shaffer, Christopher L ^b   Brady, Joseph T ^b   Houle, Christopher ^b  

^a GENENTECH INC   (United States)

^b PFIZER INC   (United States)

Author keywords

adverse drug reactions; macaques; metabotropic glutamate receptor 5 (mGluR5); Parkinson's disease; skin lesions; type IV hypersensitivity

Indexed keywords

METABOTROPIC RECEPTOR 5; NOOTROPIC AGENT; PF 06297470; PF 06422913; PF 06462894; UNCLASSIFIED DRUG; ANTIPARKINSON AGENT; FUSED HETEROCYCLIC RINGS; PF-06297470; PF-06422913; PF-06462894; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; B LYMPHOCYTE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL VACUOLE; CLINICAL OBSERVATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DRUG HYPERSENSITIVITY; ERYTHEMA; FEMALE; HELPER CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; KERATINOCYTE; MACACA FASCICULARIS; MACROPHAGE; MALE; MAXIMUM PLASMA CONCENTRATION; NECROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN DEFECT; TOXICOKINETICS; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG ERUPTIONS; PATHOLOGY;

ANIMALS; ANTIPARKINSON AGENTS; DRUG ERUPTIONS; FEMALE; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HETEROCYCLIC COMPOUNDS, 3-RING; IMMUNOHISTOCHEMISTRY; MACACA FASCICULARIS; MALE; PYRIDINES; RECEPTOR, METABOTROPIC GLUTAMATE 5;

EID: 84942887772     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623315588114     Document Type: Article

References (19)

1. Aarnink A., Estrade L., Apoil P. A., Kita Y. F., Saitou N., Shiina T., Blancher A., (2010). Study of cynomolgus monkey (Macaca fascicularis) DRA polymorphism in four populations. Immunogenetics 62, 123-36.
2. Bigby M., Jick S., Jick H., Arndt K., (1986). Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA 256, 3358-63.
3. Domin H., Szewczyk B., Wozniak M., Wawrzak-Wlecial A., Smialowska M., (2014). Antidepressant-like effect of the mGluR5 antagonist MTEP in an astroglial degeneration model of depression. Behav Brain Res 273, 23-33.
4. Downey A., Jackson C., Harun N., Cooper A., (2012). Toxic epidermal necrolysis: Review of pathogenesis and management. J Am Acad Dermatol 66, 995-1003.
5. Emmitte K. A., (2013). mGlu5 negative allosteric modulators: A patent review (2010-2012). Expert Opin Ther Pat 23, 393-408.
6. Frati C., Marchese C., Fisichella G., Copani A., Nasca M. R., Storto M., Nicoletti F., (2000). Expression of functional mGlu5 metabotropic glutamate receptors in human melanocytes. J Cell Physiol 183, 364-72.
7. Gerull R., Nelle M., Schaible T., (2011). Toxic epidermal necrolysis and Stevens-Johnson syndrome: A review. Crit Care Med 39, 1521-32.
8. Hausmann O., Schnyder B., Pichler W. J., (2010). Drug hypersensitivity reactions involving skin. In Handbook of Experimental Pharmacology: Adverse Drug Reactions (Uetrecht Jack, ed.), Vol. 196, pp. 29-55. Springer-Verlag, Berlin, Heidelberg.
9. Jordon R. E., Kawana S., Fritz K. A., (1985). Immunopathologic mechanisms in pemphigus and bullous pemphigoid. J Invest Dermatol 85, 72s-78s.
10. Marshall N. B., Swain S. L., (2011). Cytotoxic CD4 T cells in antiviral immunity. J Biomed Biotechnol 2011, 954602.
11. Olson H., Betton G., Robinson D., Thomas K., Monro A., Kolaja G., Lilly P., Sanders J., Sipes G., Bracken W., Dorato M., Van Deun K., Smith P., Berger B., Heller A., (2000). Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32, 56-67.
12. Pichler W. J., (2003). Delayed drug hypersensitivity reactions. Ann Inter Med 139, 683-93.
13. Pop A. S., Gomez-Mancilla B., Neri G., Willemsen R., Gasparini F., (2014). Fragile X syndrome: A preclinical review on metabotropic glutamate receptor 5 (mGluR5) antagonists and drug development. Psychopharmacology 231, 1217-26.
14. Rawlins M., Thompson W., (1991). Mechanisms of adverse drug reactions. In Textbook of Adverse Drug Reactions (Davies D. M., ed.), pp. 18-45. Oxford University Press, New York.
15. Shenton J. M., Teranishi M., Abu-Asab M. S., Yager J. A., Uetrecht J. P., (2003). Characterization of a potential animal model of an idiosyncratic drug reaction: Nevirapine-induced skin rash in the rat. Chem Res Toxicol 16, 1078-89.
16. Thanvi B., Lo N., Robinson T., (2007). Levodopa-induced dyskinesia in Parkinson's disease: Clinical features, pathogenesis, prevention and treatment. Postgrad Med J 83, 384-88.
17. Uetrecht J., (2007). Idiosyncratic drug reactions: Current understanding. Annu Rev Pharmacol Toxicol 47, 513-39.
18. Uetrecht J., Naisbitt D. J., (2013). Idiosyncratic adverse drug reactions: Current concepts. Pharmacol Rev 65, 779-808.
19. Williams S. C., (2012). Drugs targeting mGluR5 receptor offer "fragile" hope for autism. Nat Med 18, 840.